Phenoxazine derivatives inactivate human cytomegalovirus, herpes simplex virus-1, and herpes simplex virus-2 in vitro

被引:22
作者
Hayashi, Kyoko [3 ]
Hayashi, Toshimitsu [3 ]
Tomoda, Akio [1 ,2 ]
机构
[1] Tokyo Med Univ, Dept Biochem, Tokyo 1608404, Japan
[2] Tokyo Med Univ, Intractable Immune Syst Dis Res Ctr, Tokyo 1608404, Japan
[3] Toyama Univ, Grad Sch Med Pharmaceut Sci, Toyama 9300194, Japan
关键词
human cytomegalovirus; herpes simplex virus type 1; herpes simplex virus type 2; phenoxazine;
D O I
10.1254/jphs.FP0071679
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined whether phenoxazine derivatives, 2-amino-4,4 alpha-dihydro-4 alpha-7-dimetliyl-3H-plienoxazi ne-3-one (Phx-1), 3-arnino-1,4 alpha-dihydro-4 alpha-8-dimethyl-2H-plienoxazine-2-one (Phx-2), and 2-amino-phenoxazine-3-one (Phx-3) may have antiviral activity against herpes family viruses: human cytomegalovirus (HCMV), herpes simplex virus type I (HSV-1), and herpes simplex virus type 2 (HSV-2). The antiviral activity was evaluated by the selectivity index (SI), which is the ratio of 50% cytotoxic concentration (CC50) and 50% antiviral concentration (IC50). Among these phenoxazines, Phx-2 exerted strong antiviral activity to HCMV with the SI of 200, while Phx-1 and Phx-3 exerted no marked anti-HCMV activity. Phx-2 also showed moderate inhibition of HSV-1 and HSV-2, with the SI of 6.7 and 17, respectively. In the time-of-addition experiments, inhibitory effect of Phx-2 against HCMV was active even when applied to cells at 100 h after HCMV infection, while ganciclovir (GCV) showed potent inhibition when applied to cells before 42-h post-infection, but its inhibitory effects disappeared thereafter. Attachment and penetration of HCMV was not affected by the presence of Phx-2. When HCMV was pretreated with Phx-2, concentration-dependent virucidal action was observed, suggesting that Phx-2 inactivates HCMV directly. From these data, it was found that Phx-2 might have a different anti-HCMV target from GCV.
引用
收藏
页码:369 / 375
页数:7
相关论文
共 29 条
[1]   INVITRO VIRUCIDAL ACTIVITY OF SELECTED ANTHRAQUINONES AND ANTHRAQUINONE DERIVATIVES [J].
ANDERSEN, DO ;
WEBER, ND ;
WOOD, SG ;
HUGHES, BG ;
MURRAY, BK ;
NORTH, JA .
ANTIVIRAL RESEARCH, 1991, 16 (02) :185-196
[2]   Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models [J].
Azuine, MA ;
Tokuda, H ;
Takayasu, J ;
Enjyo, F ;
Mukainaka, T ;
Konoshima, T ;
Nishino, H ;
Kapadia, GJ .
PHARMACOLOGICAL RESEARCH, 2004, 49 (02) :161-169
[3]   THE BIOCHEMISTRY OF CANCER OF THE BLADDER [J].
BOYLAND, E .
BRITISH MEDICAL BULLETIN, 1958, 14 (02) :153-&
[4]  
ELION GB, 1982, AM J MED, V73, P7, DOI 10.1016/0002-9343(82)90055-9
[5]   The phenoxazine derivative Phx-1 suppresses IgE-mediated degranulation in rat basophilic leukemia RBL-2H3 cells [J].
Enoki, E ;
Sada, K ;
Qu, XJ ;
Kyo, S ;
Miah, SMS ;
Hatani, T ;
Tomoda, A ;
Yamamura, H .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 (03) :329-333
[6]   GANCICLOVIR - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CYTOMEGALOVIRUS INFECTIONS [J].
FAULDS, D ;
HEEL, RC .
DRUGS, 1990, 39 (04) :597-638
[7]   Antiviral targets of a chromene derivative from Sargassum micracanthum in the replication of human cytomegalovirus [J].
Hayashi, Kyoko ;
Mori, Jun ;
Saito, Haruo ;
Hayashi, Toshirnitsu .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (09) :1843-1847
[8]   A study on the perturbation of model lipid membranes by phenoxazines [J].
Hendrich, Andrzej B. ;
Stanczak, Kamila ;
Komorowska, Malgorzata ;
Motohashi, Noboru ;
Kawase, Masami ;
Michalak, Krystyna .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (17) :5948-5954
[9]  
HUANG HC, 1991, EUR J PHARMACOL, V198, P211
[10]   Suppression of proliferation of poliovirus and porcine parvovirus by novel phenoxazines, 2-amino-4,4α-dihydro-4α-7-dimethyl-3H-phenoxazine-3-one and 3-amino-1,4α-dihydro-4α-8-dimethyl-2H-phenoxazine-2-one [J].
Iwata, A ;
Yamaguchi, T ;
Sato, K ;
Yoshitake, N ;
Tomoda, A .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (05) :905-907